Antimicrobial Wound Matrix

Microlyte® Matrix absorbs wound fluid and transforms into a bioresorbable gel that intimately contours to the underlying wound bed to maintain a physiologically moist microenvironment. Silver in the matrix kills 99.99% of bacteria for several days while employing up to 100 times less silver than cover dressings or topical solutions. It reduces the risk of silver toxicity and staining, making it safe for use at the onset of any wound management plan, including burns, donor sites, diabetic ulcers and pressure sores.

Antibiofilm Wound Matrix

Ultrathin, bioresorbable Microlyte® Matrix, that synergistically employ antibiofilm transition metal Gallium and antimicrobial Silver to disrupt biofilms under wound dressings. The matrix prevents formation of bacterial biofilms on a wound-bed and kill bacteria living inside established biofilms. Optimal for application at the onset of wound treatment plan for wounds at risk of infection, and for chronic wounds with signs of biofilms.

Anesthetic Wound Matrix

Ultrathin bioresorbable wound matrix containing minuscule loadings of local anesthetics to relieve local pain in surgical wounds. The Microlyte® Matrix technology provides sustained release of anesthetics in the localized microenvironment of a wound-bed, increasing retention time of anesthetic. The matrix can reduce up to 100 times the amount of anesthetics required to relieve local pain (compared to topical or oral formulations), circumventing risks of potential side-effects or addiction in patients with severe or chronic wounds.



Antimicrobial wound matrix market


Wound infection under biologic dressings


Patients with burns and chronic ulcers in the US and EU


Growth rate for antimicrobial wound dressings market